Month: August 2011

FDA Approval

First Gene-Targeted Drug for Melanoma Approved by FDA

August 17, 2011 0

First Gene-Targeted Drug for Melanoma Approved by FDA PR Newswire WASHINGTON, Aug. 17, 2011 Decision Opens New Doors to Long-Awaited Combination Trials WASHINGTON , Aug. 17, 2011 /PRNewswire-USNewswire/ — Melanoma patients who have long faced a bleak treatment landscape are gaining a new approach for treating the deadliest form of skin cancer. […]

Stock Analysts

Regency Consolidates in Minneapolis (DDR) (DDR) (REG)

August 17, 2011 0

Regency Centers Corporation ( REG ) recently completed the acquisition of Rockridge Center, a 125,213 square foot neighborhood shopping center in Minneapolis anchored by Cub Foods for $20.5 million from private real estate development company Hempel Properties. Rockridge Center is an important and valuable acquisition for Regency Centers as it is favorably located in a densely populated area with high disposable income. […]

Stock Analysts

Qiagen Partners with Pfizer (MYGN) (PFE) (QGEN)

August 17, 2011 0

Recently, Qiagen ( QGEN ) entered into an agreement with Pfizer Inc . ( PFE ) to develop a companion molecular diagnostic test for use with an investigational Pfizer compound for treating non-small cell lung cancer (NSCLC). Financial terms of the deal were not disclosed […]

Stock Analysts

Red Robin Outperforms in 2Q (DPZ) (RRGB)

August 17, 2011 0

Casual dining restaurant operator Red Robin Gourmet Burgers Inc. ( RRGB ) reported adjusted earnings of 48 cents per share in the second quarter of 2011, handily beating the Zacks Consensus Estimate of 36 cents and the year-ago quarter earnings of 29 cents. However, including executive transition and severance expense, GAAP net income in the reported quarter was $6.9 million or 44 cents per share. […]

Stock Analysts

Move Beats By a Penny (MOVE)

August 17, 2011 0

Online real estate services provider Move, Inc. ( MOVE ) reported revenues of $48.9 million in the second quarter of 2011, up 1.2% year over year. Adjusted EBITDA (Earnings from continuing operations before interest, taxes, stock-based compensation and charges, depreciation, amortization and other non-recurring charges) came in at $6.1 million or 12.6% of revenues compared to $5.6 million or 11% of total revenues in the year-ago quarter […]

Stock Analysts

FDA Approves Abbott’s Drug (ABT)

August 17, 2011 0

Abbott Laboratories ( ABT ) recently announced that the US Food and Drug Administration (FDA) approved two new strengths of Lupron Depot-PED (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP). These new strengths are for three-month administration. CPP causes children to enter puberty early in life, resulting in the development and progression of secondary sex characteristics such as breast development in females and genital development in both males and females, resulting in shorter height […]